NCT03184168View on ClinicalTrials.gov

Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

August 7, 2017

Study Completion Date

August 25, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]lorlatinib

Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)

Trial Locations (1)

53704

Covance Clinical Research Unit Inc., Madison

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03184168 - Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers | Biotech Hunter | Biotech Hunter